secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2022-12-29T23:59:59+00:00
Accession:  0001213900-22-083558
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure
--------------------------------------------------------------------------------

- Received Nasdaq notice on Dec 22, 2022 for non-compliance with minimum $1.00 bid price rule.
- Closing bid price below $1.00 for last 30 consecutive business days triggered the notice.
- Compliance deadline is June 20, 2023; must close at $1.00+ for 10 consecutive days.
- Eligible for additional 180-day cure period if meeting other listing requirements and pursuing reverse split.
- Company is evaluating options to regain compliance; no immediate delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390022083558/0001213900-22-083558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390022083558/ea170895-8k_virpax.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-083558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer